Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX".
In June 2013, Novavax acquired the Matrix-MTM adjuvant platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.
In 2015 the company received an $89 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization.
In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40 and led the company to lay off 30% of its employees.